β-Endorphin inhibits phagocytic activity of lizard splenic phagocytes through μ receptor-coupled adenylate cyclase-protein kinase A signaling pathway

Gen Comp Endocrinol. 2011 May 1;171(3):301-8. doi: 10.1016/j.ygcen.2011.02.008. Epub 2011 Feb 23.

Abstract

The receptor-coupled intracellular signaling mechanism of endogenous opioid peptide β-endorphin (β-end) is explored for the first time in ectothermic vertebrates using wall lizard as a model. β-End inhibited the percentage phagocytosis and phagocytic index of lizard splenic phagocytes in a dose-dependent manner. The inhibitory effect of β-end on phagocytosis was completely antagonized by non-selective opioid receptor antagonist naltrexone and also by selective μ-receptor antagonist CTAP. However, selective antagonists for other opioid receptors like NTI for δ-receptor and NorBNI for κ-receptor did not alter the effect of β-end on phagocytosis. This suggests that β-end mediated its inhibitory effect on phagocytic activity of splenic phagocytes exclusively through μ opioid receptors. The μ opioid receptor-coupled downstream signaling cascade was subsequently explored using inhibitors of adenylate cyclase (SQ 22536) and protein kinase A (H-89). Both SQ 22536 and H-89 abolished the inhibitory effect of β-end on phagocytosis in a concentration-related manner. Implication of cAMP as second messenger was corroborated by cAMP assay where an increase in intracellular cAMP level was observed in response to β-end treatment. It can be concluded that β-end downregulated the phagocytic activity of lizard splenic phagocytes through μ opioid receptor-coupled adenylate cyclase-cAMP-protein kinase A pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adenylyl Cyclase Inhibitors
  • Adenylyl Cyclases / metabolism*
  • Animals
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Isoquinolines / pharmacology
  • Lizards
  • Naltrexone / pharmacology
  • Peptides / pharmacology
  • Phagocytes / cytology
  • Phagocytes / drug effects*
  • Phagocytosis / drug effects*
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Receptors, Opioid, mu / metabolism*
  • Signal Transduction / drug effects
  • Spleen / cytology*
  • Sulfonamides / pharmacology
  • beta-Endorphin / pharmacology*

Substances

  • Adenylyl Cyclase Inhibitors
  • Isoquinolines
  • Peptides
  • Receptors, Opioid, mu
  • Sulfonamides
  • 9-(tetrahydro-2-furyl)-adenine
  • Naltrexone
  • beta-Endorphin
  • connective tissue-activating peptide
  • Cyclic AMP-Dependent Protein Kinases
  • Adenylyl Cyclases
  • Adenine
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide